Tudor Investment Corp ET AL reduced its position in Qiagen N.V. (NASDAQ:QGEN) by 42.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,358 shares of the company’s stock after selling 7,015 shares during the period. Tudor Investment Corp ET AL’s holdings in Qiagen N.V. were worth $271,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Frontier Capital Management Co. LLC raised its position in shares of Qiagen N.V. by 43.7% in the first quarter. Frontier Capital Management Co. LLC now owns 2,449,006 shares of the company’s stock worth $70,948,000 after buying an additional 744,890 shares during the last quarter. Legal & General Group Plc raised its position in shares of Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock worth $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Qiagen N.V. during the first quarter worth $46,480,000. Finally, Renaissance Technologies LLC raised its position in shares of Qiagen N.V. by 182.9% in the first quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock worth $43,890,000 after buying an additional 979,498 shares during the last quarter. Institutional investors own 60.07% of the company’s stock.
Shares of Qiagen N.V. (QGEN) traded down 0.60% on Friday, reaching $31.25. 469,055 shares of the company traded hands. The company has a 50-day moving average of $32.99 and a 200-day moving average of $31.27. The stock has a market capitalization of $7.13 billion, a price-to-earnings ratio of 95.57 and a beta of 1.14. Qiagen N.V. has a 1-year low of $24.89 and a 1-year high of $35.26.
Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter in the previous year, the company earned $0.24 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Analysts anticipate that Qiagen N.V. will post $1.22 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/tudor-investment-corp-et-al-lowers-stake-in-qiagen-n-v-qgen-updated-updated-updated.html.
A number of brokerages have weighed in on QGEN. Evercore ISI boosted their target price on shares of Qiagen N.V. from $30.00 to $31.50 and gave the company an “outperform” rating in a research note on Thursday, May 4th. TheStreet upgraded shares of Qiagen N.V. from a “c” rating to a “b” rating in a research note on Monday, June 5th. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 15th. BidaskClub lowered shares of Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 10th. Finally, Barclays PLC reiterated an “overweight” rating and set a $37.00 target price (up from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $33.17.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.